Cancer Medicine (2020-01-01)

Connect MM Registry as a national reference for United States multiple myeloma patients

  • Sikander Ailawadhi,
  • Sundar Jagannath,
  • Mohit Narang,
  • Robert M. Rifkin,
  • Howard R. Terebelo,
  • Kathleen Toomey,
  • Brian G. M. Durie,
  • James W. Hardin,
  • Cristina J. Gasparetto,
  • Lynne Wagner,
  • James L. Omel,
  • Vivek Kumar,
  • Lihua Yue,
  • Amani Kitali,
  • Amit Agarwal,
  • Rafat Abonour,
  • on behalf of Connect MM Registry Investigators

DOI
https://doi.org/10.1002/cam4.2656
Journal volume & issue
Vol. 9, no. 1
pp. 35 – 42

Abstract

Read online

Abstract Background The Surveillance, Epidemiology, and End Results (SEER) database and National Cancer Database (NCDB) show improved overall survival (OS) in patients with multiple myeloma (MM) over the last 15 years. This analysis evaluated the validity of the largely community‐based Connect MM Registry as a national reference for MM. Methods Baseline disease characteristics and survival in US newly diagnosed MM patients were examined using the Connect MM Registry as well as SEER and NCDB databases. Baseline characteristics predictive of longer survival in Connect MM were also identified. Results As of February 2017, 3011 patients were enrolled in the Connect MM Registry; 2912 were treated. Median age at time of MM diagnosis and age range were numerically similar from 2010 to 2015 across all 3 registries; SEER had a higher representation of nonwhite racial groups than that in the other 2 registries. OS rates suggest proportionate improvement with year of diagnosis among the 3 registries. A Cox proportional hazards model suggests that younger age (<65 years) is associated with longer survival (vs ≥75; HR, 0.39; 95% confidence interval, 0.34‐0.46) in the Connect MM Registry. However, sex (HR, 0.91; P = .15) and race (black vs white; HR, 0.88; P = .21) were not associated with longer OS. Conclusions Data from the Connect MM Registry appear to be largely representative of national trends, comprehensive, and reliable representations of the national MM population. Baseline characteristics were comparable, and survival similarly improved over time among the 3 registries. ClinicalTrials.gov, identifier NCT01081028.

Keywords